International Pediatric HAE Guideline Recommends KalVista’s EKTERLY as First-Line Acute Therapy for Adolescents 12+

Reuters

Yesterday

International Pediatric HAE Guideline Recommends KalVista’s EKTERLY as First-Line Acute Therapy for Adolescents 12+

KalVista Pharmaceuticals Inc. said a newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema attacks in adolescents aged 12 and older. The company noted EKTERLY launched in the U.S. and Germany months ago and received seven global regulatory approvals in 2025, and said it is approved in the U.S., EU, UK, Switzerland, Australia, Singapore and Japan for acute HAE attacks in patients 12 and older. KalVista also said it is advancing the KONFIDENT-KID trial and plans to submit a new drug application for sebetralstat in patients aged 2 to 11 in the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260218359223) on February 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612485464"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612485464\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612485464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612485464","market":"nz","top_or_hot":-1,"title":"International Pediatric HAE Guideline Recommends KalVista’s EKTERLY as First-Line Acute Therapy for Adolescents 12+","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      International Pediatric HAE Guideline Recommends KalVista’s EKTERLY as First-Line Acute Therapy for Adolescents 12+\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. said a newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema attacks in adolescents aged 12 and older. The company noted EKTERLY launched in the U.S. and Germany months ago and received seven global regulatory approvals in 2025, and said it is approved in the U.S., EU, UK, Switzerland, Australia, Singapore and Japan for acute HAE attacks in patients 12 and older. KalVista also said it is advancing the KONFIDENT-KID trial and plans to submit a new drug application for sebetralstat in patients aged 2 to 11 in the third quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260218359223) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>International Pediatric HAE Guideline Recommends KalVista’s EKTERLY as First-Line Acute Therapy for Adolescents 12+</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInternational Pediatric HAE Guideline Recommends KalVista’s EKTERLY as First-Line Acute Therapy for Adolescents 12+\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      International Pediatric HAE Guideline Recommends KalVista’s EKTERLY as First-Line Acute Therapy for Adolescents 12+\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. said a newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema attacks in adolescents aged 12 and older. The company noted EKTERLY launched in the U.S. and Germany months ago and received seven global regulatory approvals in 2025, and said it is approved in the U.S., EU, UK, Switzerland, Australia, Singapore and Japan for acute HAE attacks in patients 12 and older. KalVista also said it is advancing the KONFIDENT-KID trial and plans to submit a new drug application for sebetralstat in patients aged 2 to 11 in the third quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260218359223) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALV","symbol_name":"Kalvista Pharmaceuticals Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL3qyjZD:1","article_id":"2612485464","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612485464","pubTimestamp":1771416126,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"KalVista Pharmaceuticals Inc. said a newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY  as a first-line therapy for the acute treatment of hereditary angioedema attacks in adolescents aged 12 and older. The company noted EKTERLY launched in the U.S. and Germany months ago and received seven global regulatory approvals in 2025, and said it is approved in the U.S., EU, UK, Switzerland, Australia, Singapore and Japan for acute HAE attacks in patients 12 and older. KalVista also said it is advancing the KONFIDENT-KID trial and plans to submit a new drug application for sebetralstat in patients aged 2 to 11 in the third quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"国际儿科HAE指南推荐KalVista的EKTERLY作为12+青少年的一线急性疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9},"content_text":"International Pediatric HAE Guideline Recommends KalVista’s EKTERLY as First-Line Acute Therapy for Adolescents 12+\n    \n\n        KalVista Pharmaceuticals Inc. said a newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema attacks in adolescents aged 12 and older. The company noted EKTERLY launched in the U.S. and Germany months ago and received seven global regulatory approvals in 2025, and said it is approved in the U.S., EU, UK, Switzerland, Australia, Singapore and Japan for acute HAE attacks in patients 12 and older. KalVista also said it is advancing the KONFIDENT-KID trial and plans to submit a new drug application for sebetralstat in patients aged 2 to 11 in the third quarter of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260218359223) on February 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}